Allarity Therapeutics Showcases Phase 2 Stenoparib Trial Design at ESMO 2026
COPENHAGEN, Denmark, June 18, 2026 Allarity Therapeutics, Inc. announced the presentation of a Trial-in-Progress poster for its ongoing Phase...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
COPENHAGEN, Denmark, June 18, 2026 Allarity Therapeutics, Inc. announced the presentation of a Trial-in-Progress poster for its ongoing Phase...
MUMBAI, India & NAPLES, Fla., June 17, 2026 Lupin Limited, a leading global pharmaceutical company, has announced the launch...
LOS ANGELES, Calif., June 18, 2026 TORL BioTherapeutics has reported encouraging preliminary Phase 1 clinical data for its investigational...
SAN JOSE, Calif., June 11, 2026 Anixa Biosciences, Inc. announced that two of its clinical-stage cancer immunotherapy programs will...
MAINZ, Germany, May 22, 2026 BioNTech announced new clinical data presentations and pipeline updates from its expanding late-stage oncology...
NANTES, France, May 22, 2026 OSE Immunotherapeutics announced positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi®...
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026 BriaCell Therapeutics announced the expansion of its oncology pipeline with the...
BURLINGTON, N.C., April 22, 2026 Labcorp announced the nationwide availability of the FDA-approved PD-L1 IHC 22C3 pharmDx companion diagnostic,...
London, United Kingdom | April 13, 2026 GSK plc has announced positive clinical data from its Phase 1 BEHOLD-1...
North Chicago, Illinois | April 12, 2026 AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy...
